Welcome to our dedicated page for Vyome Holdings news (Ticker: HIND), a resource for investors and traders seeking the latest updates and insights on Vyome Holdings stock.
Vyome Holdings, Inc. develops clinical-stage specialty pharmaceutical therapies for immune-inflammatory and rare conditions. Company news centers on VT-1953, a topical gel program for malodor and other symptoms of malignant fungating wounds in cancer patients, and VT-1908, a repurposed immune modulator being studied for uveitis.
Recurring updates include clinical and preclinical data presentations, regulatory submissions and development planning, capital-structure actions, material agreements, shareholder voting matters, and operating or financial results tied to Vyome’s pharmaceutical and biotechnology activities.
Vyome (NASDAQ:HIND) received a new Chinese patent covering formulation and therapeutic use claims for its besifloxacin topical gel for inflammatory acne. The patent broadens protection to acne, associated inflammation, and antibiotic-resistant Propionibacterium acnes in China, an estimated $600 million prescription acne market, supporting future partnering and regional commercialization.
Vyome Holdings (Nasdaq:HIND) reported Q1 2026 results and regulatory progress. The company ended the quarter with approximately $8.8 million in cash and no debt, preferred stock, or toxic financing instruments. Net loss was about $963,000, or $0.15 per share.
Vyome advanced VT-1953 toward pivotal readiness, submitted an FDA Orphan Drug Designation application, and presented positive Phase 2 data. It also in-licensed selective JAK inhibitor assets from Impetis Biosciences and raised roughly $5.29 million in equity, implying around 15% dilution.
Vyome (Nasdaq: HIND) presented Phase 2 data showing VT-1953 gel produced statistically significant reductions in malignant fungating wound (MFW) malodor and pain by Day 14 (primary endpoint: median TELER score improved from 0.5 to 4; P=0.0020).
Additional highlights: superiority versus vehicle (P=0.0015), 70% of VT-1953 patients reported improved malodor impact versus 0% for vehicle (P=0.0256), a 2-point median pain improvement (P=0.0020), and no treatment-emergent adverse effects reported.
Vyome (Nasdaq: HIND) will present complete Phase 2 clinical and supporting preclinical data for VT-1953 as a potential treatment for malodor and symptoms of malignant fungating wounds (MFW) at AACR 2026 on April 21, 2026.
Vyome said VT-1953 is first-in-class with a dual mechanism (DNA Gyr inhibition and MD2/TLR modulation). The company plans FDA interactions in Q2 2026 and is advancing VT-1953 toward pivotal studies; third-party analysts estimate a ~USD 2.2 billion U.S. TAM. MFW affects ~10% of advanced cancer patients.
Vyome (Nasdaq: HIND) completed a streamlined Nasdaq listing via merger, holds a clean capital structure with 5,919,337 common shares and no preferred stock or debt. Final Phase 2 data for VT-1953 showed statistically significant malodor reduction (P<0.002) and favorable safety.
Total cash was approximately $4.94M at 12/31/2025 plus an $5.3M ATM financing in Jan 2026, supporting runway to mid-2027; independent valuation placed VT-1953 at ~$1B post-Phase 3.
Livechain (subsidiary of Vyome; Nasdaq: HIND) acquired senior, secured convertible debt of Humanyze via an all‑stock purchase and initiated a default and asset transfer to assume Humanyze's business assets and operations.
Livechain issued common stock valued at approximately $325,000 to Remus Capital and said the deal creates a path to seek a possible uplisting to a national exchange in 2026.
Vyome (Nasdaq: HIND) announced publication of preclinical results showing topical VT-1908 reduced uveitis scores (p<0.001) and lowered anterior chamber lymphocytes with no irritation or toxicity in an animal model. VT-1908 matched topical prednisone in efficacy preclinically. The company plans to advance VT-1908 into human studies via the India innovation corridor while keeping its capital deployment unchanged and maintaining focus on the Phase 3 program for lead asset VT-1953.
Vyome (NASDAQ: HIND) filed for Orphan Drug Designation for VT-1953, its lead clinical asset for malignant fungating wounds (MFW).
Key points: potential 7 years U.S. market exclusivity, up to 25% R&D tax credits, a PDUFA fee waiver (~$3M), a third-party rNPV valuation of $455M today and ~$1B post-Phase 3, planned FDA Phase 3 interactions in Q2 2026, CROs engaged, and interim Phase 3 results expected in mid-2027.
Vyome Holdings (Nasdaq: HIND) funded the estimated costs to reach initial Phase 3 interim results for VT-1953, aimed at treating symptoms of Malignant Fungating Wounds, using its existing ATM facility. On January 27, 2026, the company sold 1,089,045 shares at an average price of $5.00, generating approximately $5.29 million net proceeds.
As of January 29, 2026, Vyome reported $9.5 million cash on hand and total shares outstanding of 7,008,882. Management says interim Phase 3 findings are anticipated in mid-2027.
Vyome (NASDAQ: HIND) released results of an independent U.S. market and valuation analysis for lead candidate VT-1953 on January 27, 2026. The third‑party study estimates the U.S. total addressable pharmacologic market for malignant fungating wounds at USD 2.2 billion, modeled peak annual net sales for VT-1953 at ~USD 600 million, a current risk‑adjusted asset value of USD 455 million given positive Phase 2 data, and a post‑Phase 3 rNPV approaching USD 1 billion. The analysis used epidemiology modeling, pricing benchmarking, clinician interviews, and rNPV methodology and notes no FDA‑approved drugs currently exist for this indication.